227 related articles for article (PubMed ID: 30500189)
21. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
Karabanovich G; Dušek J; Savková K; Pavliš O; Pávková I; Korábečný J; Kučera T; Kočová Vlčková H; Huszár S; Konyariková Z; Konečná K; Jand'ourek O; Stolaříková J; Korduláková J; Vávrová K; Pávek P; Klimešová V; Hrabálek A; Mikušová K; Roh J
J Med Chem; 2019 Sep; 62(17):8115-8139. PubMed ID: 31393122
[TBL] [Abstract][Full Text] [Related]
22. Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains.
Liu J; Dai H; Wang B; Liu H; Tian Z; Zhang Y
Eur J Med Chem; 2022 Jan; 227():113932. PubMed ID: 34700267
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
[TBL] [Abstract][Full Text] [Related]
24. Virtual Screening of Small Molecular Inhibitors against DprE1.
Zhang G; Guo S; Cui H; Qi J
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
[TBL] [Abstract][Full Text] [Related]
25. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
Dash S; Rathi E; Kumar A; Chawla K; Kini SG
Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.
Li P; Wang B; Zhang X; Batt SM; Besra GS; Zhang T; Ma C; Zhang D; Lin Z; Li G; Huang H; Lu Y
Eur J Med Chem; 2018 Dec; 160():157-170. PubMed ID: 30336450
[TBL] [Abstract][Full Text] [Related]
28. 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
Naik M; Humnabadkar V; Tantry SJ; Panda M; Narayan A; Guptha S; Panduga V; Manjrekar P; Jena LK; Koushik K; Shanbhag G; Jatheendranath S; Manjunatha MR; Gorai G; Bathula C; Rudrapatna S; Achar V; Sharma S; Ambady A; Hegde N; Mahadevaswamy J; Kaur P; Sambandamurthy VK; Awasthy D; Narayan C; Ravishankar S; Madhavapeddi P; Reddy J; Prabhakar K; Saralaya R; Chatterji M; Whiteaker J; McLaughlin B; Chiarelli LR; Riccardi G; Pasca MR; Binda C; Neres J; Dhar N; Signorino-Gelo F; McKinney JD; Ramachandran V; Shandil R; Tommasi R; Iyer PS; Narayanan S; Hosagrahara V; Kavanagh S; Dinesh N; Ghorpade SR
J Med Chem; 2014 Jun; 57(12):5419-34. PubMed ID: 24871036
[TBL] [Abstract][Full Text] [Related]
29. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
[TBL] [Abstract][Full Text] [Related]
31. Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1.
Richter A; Rudolph I; Möllmann U; Voigt K; Chung CW; Singh OMP; Rees M; Mendoza-Losana A; Bates R; Ballell L; Batt S; Veerapen N; Fütterer K; Besra G; Imming P; Argyrou A
Sci Rep; 2018 Sep; 8(1):13473. PubMed ID: 30194385
[TBL] [Abstract][Full Text] [Related]
32. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.
Esposito M; Szadocka S; Degiacomi G; Orena BS; Mori G; Piano V; Boldrin F; Zemanová J; Huszár S; Barros D; Ekins S; Lelièvre J; Manganelli R; Mattevi A; Pasca MR; Riccardi G; Ballell L; Mikušová K; Chiarelli LR
ACS Infect Dis; 2017 Jun; 3(6):428-437. PubMed ID: 28475832
[TBL] [Abstract][Full Text] [Related]
33. Synthetic molecules as DprE1 inhibitors: A patent review.
Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
[TBL] [Abstract][Full Text] [Related]
34. Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria.
Sommer R; Neres J; Piton J; Dhar N; van der Sar A; Mukherjee R; Laroche T; Dyson PJ; McKinney JD; Bitter W; Makarov V; Cole ST
ACS Chem Biol; 2018 Nov; 13(11):3184-3192. PubMed ID: 30289689
[TBL] [Abstract][Full Text] [Related]
35. DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.
Brecik M; Centárová I; Mukherjee R; Kolly GS; Huszár S; Bobovská A; Kilacsková E; Mokošová V; Svetlíková Z; Šarkan M; Neres J; Korduláková J; Cole ST; Mikušová K
ACS Chem Biol; 2015 Jul; 10(7):1631-6. PubMed ID: 25906160
[TBL] [Abstract][Full Text] [Related]
36. Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening.
Gao Y; Xie J; Tang R; Yang K; Zhang Y; Chen L; Li H
Bioorg Chem; 2019 Apr; 85():168-178. PubMed ID: 30616098
[TBL] [Abstract][Full Text] [Related]
37. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and structure activity relationship of imidazo[1,2-a]pyridine-8-carboxamides as a novel antimycobacterial lead series.
Ramachandran S; Panda M; Mukherjee K; Choudhury NR; Tantry SJ; Kedari CK; Ramachandran V; Sharma S; Ramya VK; Guptha S; Sambandamurthy VK
Bioorg Med Chem Lett; 2013 Sep; 23(17):4996-5001. PubMed ID: 23867166
[TBL] [Abstract][Full Text] [Related]
39. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1.
Trefzer C; Škovierová H; Buroni S; Bobovská A; Nenci S; Molteni E; Pojer F; Pasca MR; Makarov V; Cole ST; Riccardi G; Mikušová K; Johnsson K
J Am Chem Soc; 2012 Jan; 134(2):912-5. PubMed ID: 22188377
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1).
Matsunaga T; Monobe K; Aoki S
Infect Disord Drug Targets; 2023; 23(5):e090323214508. PubMed ID: 36892121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
